Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial
- PMID:11437015
- DOI: 10.1097/00004583-200107000-00011
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial
Abstract
Objective: This study assesses the efficacy and tolerability of fluoxetine in the acute treatment of child and adolescent obsessive-compulsive disorder (OCD) during a 13-week, double-blind, placebo-controlled study.
Method: Eligible patients aged 7 to 17 (N = 103) were randomized at a ratio of 2:1 to receive either fluoxetine or placebo. Dosing was initiated at 10 mg daily for 2 weeks, then increased to 20 mg daily. After 4 weeks of treatment, and again after 7 weeks of treatment, non-responders could have their dosage increased by 20 mg daily, for a maximum possible dosage of 60 mg daily. Primary measure of efficacy was improvement in OCD symptoms as measured by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS). All analyses were intent-to-treat.
Results: Fluoxetine was associated with significantly greater improvement in OCD as assessed by the CY-BOCS (p = .026) and other measures than was placebo. Fluoxetine was well tolerated and had a rate of discontinuation for adverse events similar to that of placebo (p = 1.00).
Conclusions: Fluoxetine 20 to 60 mg daily was effective and well tolerated for treatment of OCD in this pediatric population.
Comment in
- Paroxetine in adolescent major depression.Weintrob A.Weintrob A.J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):363-4; author reply 364. doi: 10.1097/00004583-200204000-00002.J Am Acad Child Adolesc Psychiatry. 2002.PMID:11931587No abstract available.
Similar articles
- Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, Graae F, Jaffer M, Lin SH, Sallee FR, Schmidt AB, Simpson HB.Liebowitz MR, et al.J Am Acad Child Adolesc Psychiatry. 2002 Dec;41(12):1431-8. doi: 10.1097/00004583-200212000-00014.J Am Acad Child Adolesc Psychiatry. 2002.PMID:12447029Clinical Trial.
- Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ.Riddle MA, et al.J Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1062-9. doi: 10.1097/00004583-199211000-00011.J Am Acad Child Adolesc Psychiatry. 1992.PMID:1429406Clinical Trial.
- A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).Alaghband-Rad J, Hakimshooshtary M.Alaghband-Rad J, et al.Eur Child Adolesc Psychiatry. 2009 Mar;18(3):131-5. doi: 10.1007/s00787-007-0634-z. Epub 2009 Feb 3.Eur Child Adolesc Psychiatry. 2009.PMID:19190958Clinical Trial.
- A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.Pigott TA, Seay SM.Pigott TA, et al.J Clin Psychiatry. 1999 Feb;60(2):101-6. doi: 10.4088/jcp.v60n0206.J Clin Psychiatry. 1999.PMID:10084636Review.
- Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ.Fineberg NA, et al.Int Clin Psychopharmacol. 2007 Nov;22(6):313-22. doi: 10.1097/YIC.0b013e32825ea312.Int Clin Psychopharmacol. 2007.PMID:17917549Review.
Cited by
- Understudied clinical dimensions in pediatric obsessive compulsive disorder.Lewin AB, Caporino N, Murphy TK, Geffken GR, Storch EA.Lewin AB, et al.Child Psychiatry Hum Dev. 2010 Dec;41(6):675-91. doi: 10.1007/s10578-010-0196-z.Child Psychiatry Hum Dev. 2010.PMID:20644997
- Bone growth in juvenile rhesus monkeys is influenced by 5HTTLPR polymorphisms and interactions between 5HTTLPR polymorphisms and fluoxetine.Golub MS, Bulleri AM, Hogrefe CE, Sherwood RJ.Golub MS, et al.Bone. 2015 Oct;79:162-9. doi: 10.1016/j.bone.2015.05.042. Epub 2015 Jun 9.Bone. 2015.PMID:26067181Free PMC article.
- Contemporary assessment and pharmacotherapy of Tourette syndrome.Scahill L, Erenberg G, Berlin CM Jr, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J; Tourette Syndrome Association Medical Advisory Board: Practice Committee.Scahill L, et al.NeuroRx. 2006 Apr;3(2):192-206. doi: 10.1016/j.nurx.2006.01.009.NeuroRx. 2006.PMID:16554257Free PMC article.Review.
- Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, Kessler RC, Kossowsky J.Locher C, et al.JAMA Psychiatry. 2017 Oct 1;74(10):1011-1020. doi: 10.1001/jamapsychiatry.2017.2432.JAMA Psychiatry. 2017.PMID:28854296Free PMC article.
- Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.Martin A, Koenig K, Anderson GM, Scahill L.Martin A, et al.J Autism Dev Disord. 2003 Feb;33(1):77-85. doi: 10.1023/a:1022234605695.J Autism Dev Disord. 2003.PMID:12708582Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical